2018 Press Releases

October 11, 2018
ADA, JDRF and Helmsley Charitable Trust Announce Funding of Quantitative Analysis of Insulin Purchased from Pharmacies in the U.S.
The American Diabetes Association (ADA), JDRF International (JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust (Helmsley) together announce the awarding of funding to the University of Florida for a one-year investigation by Dr. Timothy Garrett of the consistency and potency of insulin that is purchased at retail pharmacies across the United States.

October 5, 2018
New Consensus Report from the American Diabetes Association® (ADA) and the European Association for the Study of Diabetes (EASD) Calls for Paradigm Shift to Patient-Centered Care for Type 2 Diabetes
Produced by an international panel of diabetes care experts assembled by the ADA and the EASD, the ADA-EASD Consensus Report calls for a paradigm shift to patient-centered care and details the panel’s comprehensive review of the latest evidence.

September 20, 2018
American Diabetes Association® Celebrates Culmination of Two Decades of Advocacy on Behalf of Commercial Drivers with Insulin-Treated Diabetes Following Final Rule
The American Diabetes Association (ADA) applauds the U.S. Department of Transportation, Federal Motor Carrier Safety Administration (FMCSA) for its new rule permitting individuals with insulin-treated diabetes to be certified to operate commercial motor vehicles in interstate commerce.

September 14, 2018
People with Diabetes Impacted by Hurricane Florence: National Diabetes Coalition Available to Support
The Diabetes Disaster Response Coalition (DDRC), comprised of the nation’s leading diabetes organizations, has prepared multiple online resources to support all people with diabetes, especially those who depend upon insulin, so they can continue to effectively manage their diabetes.

September 10, 2018
National Diabetes Coalition Urges People with Diabetes Living Along the East Coast to Prepare for Hurricane Florence
The Diabetes Disaster Response Coalition (DDRC), comprised of the nation’s leading diabetes organizations, is urging all people with diabetes and their loved ones to prepare for Hurricane Florence by putting together a diabetes kit and making a plan to stay healthy and safe during the storm and in its aftermath.

September 4, 2018
Patient Groups: Senate Health Care Bill Would Not Sufficiently Protect Patients with Pre-Existing Conditions
WASHINGTON, D.C., September 4, 2018 — More than 25 patient and consumer groups representing millions of people with pre-existing health conditions issued the following statement regarding S. 3388, the Ensuring Coverage for Patients with Pre-Existing Conditions Act introduced on August 23rd, 2018.

August 23, 2018
National Diabetes Coalition Urges Hawaiians Living with Diabetes to Make a Plan to Weather Hurricane Lane
The Diabetes Disaster Response Coalition (DDRC), comprised of the nation’s leading diabetes care and research organizations, is urging all people with diabetes and their loved ones in Hawaii to prepare for Hurricane Lane by putting together a diabetes kit and making a plan to stay healthy and safe during the storm and in its aftermath.

August 17, 2018
Support for American Diabetes Association’s® 2018 Summer Camps for Youth with Type 1 Diabetes Enables Advanced Training in New Diabetes Care Technologies
To help ensure camp programs are ready to support the many different types of diabetes technology at camp, the ADA convened forty-one experts to build tools, tip sheets and training resources that keep the camp experience ready to embrace state-of-the-art diabetes management technology, insulins and tools.

August 9, 2018
American Diabetes Association® Issues New Position Statement on Care for Pediatric Patients with Type 1 Diabetes
To address the specific needs of youth and adolescents, the American Diabetes Association issued “Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association” today, which is available online and will be published in the September 2018 print issue of Diabetes Care.

August 2, 2018
Final Rule on Short-Term Insurance Plans Will Leave Patients with High Costs, Less Coverage
The U.S. Departments of Labor, Treasury, and Health and Human Services issued a final rule that would expand the use of “short-term, limited-duration insurance plans.” More than 25 patient and consumer groups representing millions of people with pre-existing health conditions issued the following statement.

June 25, 2018
Diabetes Emergency Relief Coalition Wins Top Association Honor
The Diabetes Emergency Relief Coalition (Coalition), composed of leading diabetes care and research organizations, will receive the American Society of Association Executives (ASAE) 2018 Summit Power of A Award for helping to provide critical diabetes supplies to regions impacted by Hurricanes Harvey, Irma and Maria, the Coalition announced today.

June 25, 2018
Metformin Alone or Combined with Insulin Does Not Improve or Preserve Beta-Cell Function in Youth with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes
According to recent research, the insulin resistance and pancreatic beta-cell (β-cell) dysfunction associated with type 2 diabetes (T2D) was unresponsive to treatment with metformin alone or metformin combined with insulin glargine in youth with impaired glucose tolerance (IGT), which is an element of prediabetes, or early T2D.

June 25, 2018
Type 2 Diabetes Risk in Asian Indian Immigrants in U.S. Impacted by Adopted Lifestyle Habits
New research shows that Asian Indian immigrants in the U.S. are at increased risk for chronic diseases including type 2 diabetes (T2D) and cardiovascular disease (CVD). Adopting American lifestyle behaviors may specifically affect HbA1c levels and high-density lipoproteins (HDL) cholesterol levels in this group, according to the study, “Mediating Role of Acculturation and Lifestyle Behaviors on Cardiometabolic Risks among Asian Indians in the United States,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 25, 2018
Carol and Mark A. Atkinson, PhD, Receive American Diabetes Association’s Humanitarian Award
Carol and Mark A. Atkinson, PhD, of Insulin for Life USA, are the recipients of the American Diabetes Association’s® (ADA’s) Humanitarian Award. This one-time award honors their outstanding leadership and humanitarian efforts to support the diabetes community for the Diabetes Emergency Relief Coalition in 2017.

June 25, 2018
Expanded Access to Prevention Programs and Acknowledging Increased Risk of Depression Among People with Diabetes Can Reduce Complications and Prevalence, and Improve Outcomes and Quality of Life
Diabetes is a unique and complex disease affecting more than 30 million Americans, and the individual living with diabetes is solely responsible for daily diabetes management.

June 24, 2018
Alirocumab and Statins Highly Effective in People with Diabetes with Acute Coronary Syndrome
People with diabetes who have experienced recent acute coronary syndrome (ACS) and take a combination of alirocumab and statins may reduce their risk of future cardiac events by more than double that of people on the same medication regimen who have similar cardiac histories, but have prediabetes or normal blood glucose levels, according to the study, “Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Intense Multifactorial Treatment for Type 2 Diabetes Shown to be Cost Effective
When patients with type 2 diabetes (T2D) receive intensified, multifactorial treatment combining lifestyle modification and pharmacological therapy for modifiable risk factors, there is no significant increase in medical costs, compared to patients who receive conventional, multifactorial treatment, according to the study, “A Cost Analysis of Intensified vs. Conventional Multifactorial Therapy of Patients with Type 2 Diabetes—The Steno 2 Study,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Real World Study Suggests Canagliflozin Does Not Increase Risk of Below- Knee Amputation in People with Type 2 Diabetes
Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease, but does reduce a patient’s risk of hospitalization for heart failure, according to the study, “Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 24, 2018
Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control
Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in weight loss and led to a reduction in insulin doses, yet also correlated with a slight increase in diabetic ketoacidosis risk compared to placebo, according to the study “Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 24, 2018
Sotagliflozin in Conjunction with Insulin for Type 1 Diabetes Reduces Average Blood Glucose Levels
People with type 1 diabetes (T1D) who take 200 mg or 400 mg of sotagliflozin in addition to optimized insulin therapy have statistically lower HbA1c levels and weight, as well as low incidence of severe hypoglycemia after a year of treatment, compared to those who take a placebo with optimized insulin, according to the study, “Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1),” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

Items 1 - 20 of 69  1234Next